Gagliardi L, Le Jeunne C. Corticothérapie et diabète. Presse Med 2012; 41: 393-9.
Izzedine H, Launay-Vacher V, Deybach C, et al. Drug-induced diabetes mellitus. Expert Opin Drug Saf 2005; 4: 1097-109.
Capeau J, Bouteloup V, Katlama C, et al; ANRS CO8 APROCO-COPILOTE Cohort Study. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26: 303-14.
Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32: 539-46.
Scheen AJ, De Hert M. Diabète sucré iatrogène: l'exemple des anti-psychotiques atypiques. Rev Med Liège 2005; 60: 455-60.
Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007; 33: 169-75.
Bell DS, DiNicolantonio JJ, O'Keefe JH. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. Diabetes Obes Metab 2014; 16: 689-94.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429-42.
Correll CU, Sikich L, Reeves G, Riddle M. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatry 2013; 170: 947-52.
Beck E, Scheen AJ. Quels bénéfices antitumoraux attendre de la metformine ? Ann Endocrinol (Paris) 2013; 74: 137-47.
Scheen AJ. Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des maladies Métaboliques. 2015; 9: 186-97.
